inTheMedia

Healio: Eyevensys closes on $30 million Series B financing

Healio: Eyevensys closes on $30 million Series B financing 150 150 Eyevensys

Patricia Zilliox, CEO of Eyevensys discusses closing a $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis.

Dallas News: Paris and Fort Worth-based biotech company Eyevensys raises $30 million to develop treatments for eye diseases

Dallas News: Paris and Fort Worth-based biotech company Eyevensys raises $30 million to develop treatments for eye diseases 150 150 Eyevensys

Patricia Zilliox, CEO of Eyevensys discusses next steps for the company after completing a series B financing round.

Dallas Innovates: Fort Worth Biotech Eyevensys Completes $30M Series B Funding Round

Dallas Innovates: Fort Worth Biotech Eyevensys Completes $30M Series B Funding Round 150 150 Eyevensys

Patricia Zilliox, CEO of Eyevensys gives insight on how Eyevensys plans to use the $30M funding raised from its Series B round.

Medgadget: Eyevensys Non-Viral Gene Therapy for Ocular Diseases: Interview with Patricia Zilliox, CEO of Eyevensys

Medgadget: Eyevensys Non-Viral Gene Therapy for Ocular Diseases: Interview with Patricia Zilliox, CEO of Eyevensys 150 150 Eyevensys

In this interview, Patricia Zilliox, CEO of Eyevensys discusses its innovative non-viral gene therapy platform, with the aim of treating ocular diseases.

  • 1
  • 2